文献速递主动脉疾病

多重用药评分与完整主动脉髂动脉瘤且有修复指征患者长期生存的相关性

Association of polypharmacy scores with the long-term survival of patients with intact aortoiliac aneurysms and indication for repair.
PubMed 文献 · J Vasc Surg · 2023-11-03

本研究为单中心回顾性队列,纳入2008至2021年因完整腹主动脉和/或髂总动脉瘤有修复指征就诊的424例患者。ACP D>5与Rx-Risk>0均与5年死亡率升高独立相关,且两种评分均显著改善Charlson合并症指数对生存的预测区分度。

要点

  • ACP D>5与Rx-Risk>0均与完整AAA患者5年死亡率升高独立相关。
  • 两种多重用药评分对生存的预测表现相似,简单ACP D>5似已足够识别生存率较低的患者。
  • 两种评分均显著改善Charlson合并症指数对生存的预测区分度。

核心结论

  • ACP D与Rx-Risk两种多重用药评分均与有修复指征的完整AAA患者生存独立相关,两者表现相似,简单ACP D>5似已足够识别生存率较低的患者。

研究设计与样本

  • 单中心回顾性连续队列,纳入2008至2021年因完整腹主动脉和/或髂总动脉瘤有修复指征就诊的患者。
  • 共评估424例患者,中位年龄76岁,92.2%为男性,中位Charlson指数2。
  • 314例(74.1%)接受干预(80%腔内,20%开放),110例(25.9%)未接受干预。
  • 基线记录人口学数据、Charlson合并症指数、AAA治疗方式、ACP D与Rx-Risk多重用药评分。
  • 统计分析包括Cox回归、曲线下面积和连续净重分类指数。

主要发现

  • 随访期间(平均4.6年)245例(57.8%)死亡,1个月、1年和5年生存率分别为98.1%、86.3%和52.7%。
  • ACP D与Rx-Risk评分中位数(四分位距)分别为6(4-9)和3(0-5),与生存显著线性相关(P < .001),最佳截断值分别为5和0。
  • 校正年龄、性别、Charlson指数和AAA治疗类型后,ACP D>5与5年死亡率增加45.2%相关(P = .038),Rx-Risk>0与5年死亡率增加102%相关(P = .002)。
  • 两种多重用药指数均显著改善Charlson合并症指数预测生存的区分能力。

关键数值与推荐

  • ACP D>5定义为基线长期处方药物超过5种,与5年死亡率增加45.2%相关(P = .038)。
  • Rx-Risk>0与5年死亡率增加102%相关(P = .002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE/BACKGROUND: Our study analyzed the relationship between two polypharmacy scores (addition of chronic prescribed drugs [ACPDs] and Rx-Risk Comorbidity Index) and survival in patients with an intact abdominal aortic and/or common iliac aneurysm (AAA). METHODS: Consecutive retrospective, single-center cohort of patients attended for an intact AAA with indication for repair from 2008 to 2021. Demographic data, Charlson Comorbidity Index, AAA treatment, ACPD, and Rx-Risk polypharmacy scores were recorded at baseline. Main outcomes were the 5-year and long-term survival rates. The statistical analysis included Cox regression, area under the curve, and continuous net reclassification index. RESULTS: A total of 424 patients with AAA were evaluated (median age: 76 years; 92.2% male, median Charlson index 2), of whom 314 (74.1%) underwent intervention (80% endovascular and 20% open) and 110 (25.9%) did not. During follow-up (mean 4.6 years), 245 patients (57.8%) died, with 1-month, 1-year, and 5-year survival rates of 98.1%, 86.3%, and 52.7%, respectively. ACPD and Rx-Risk indices (median [interquartile range]: 6 [4-9] and 3 [0-5], respectively) were significantly and linearly associated (P < .001) with survival, with the best cutoff points at 5 and 0, respectively. An ACPD >5 (patients with >5 chronically prescribed drugs at baseline) and an Rx-Risk >0 were associated with a 45.2% (P = .038) and 102% (P = .002) increase in 5-year mortality, respectively, after adjustment for age, sex, Charlson index, and type of AAA treatment. Both polypharmacy indices improved significantly the discriminative power of the Charlson Comorbidity Index in predicting survival. CONCLUSIONS: Both ACPD and Rx-Risk polypharmacy scores are independently related to survival among patients with an intact AAA and indication for repair. Their behavior is similar, so the simple ACPD >5 appears to be sufficient to identify patients with lower survival rates.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Pumares-García L, Paredes-Mariñas E, Calsina-Juscafresa L, et al. Association of polypharmacy scores with the long-term survival of patients with intact aortoiliac aneurysms and indication for repair. J Vasc Surg. 2023. PMID: 37923020. doi:10.1016/j.jvs.2023.10.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。